ArticleNature2019
RB constrains lineage fidelity and multiple stages of tumour progression and metastasis.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 81 citations in OpenAlex.
- Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes.Nature communications · 2021Trial
- Cell plasticity in cancer and therapy resistance.Experimental & molecular medicine · 2026Review
- Blocking acid-sensing ion channel 1a attenuates bilirubin-induced ototoxicity in cochlear organotypic culture.Fundamental research · 2026Article
- RB loss modulates chromatin organization by regulating cohesin-dependent loops and enhancer-promoter interactions.Nature communications · 2026Article
- The repressor Capicua is a barrier to lung tumor development driven by Kras/Trp53 mutations.EMBO molecular medicine · 2025Article
- Lineage plasticity and histological transformation: tumor histology as a spectrum.Cell research · 2025Review
- Natural anticancer agents: prospection of medicinal and aromatic plants in modern chemoprevention and chemotherapy.Natural products and bioprospecting · 2025Review
- Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma.Molecular cell · 2025Article
- Combinatorial In Vivo Genome Editing Identifies Widespread Epistasis and an Accessible Fitness Landscape During Lung Tumorigenesis.Molecular biology and evolution · 2025Article
- Mechanisms of Regulation of Cell Fate in Breast Development and Cancer.Advances in experimental medicine and biology · 2025Review
- In vivo models of subclonal oncogenesis and dependency in hematopoietic malignancy.Cancer cell · 2024Article
- Roles of naïve CD4Journal of translational medicine · 2024Article
- Patterns in the tapestry of chromatin-bound RB.Trends in cell biology · 2024Review
- The orchestration of cell-cycle reentry and ribosome biogenesis network is critical for cardiac repair.Theranostics · 2024Article
- Review
- Metastatic Competency and Tumor Spheroid Formation Are Independent Cell States Governed by RB in Lung Adenocarcinoma.Cancer research communications · 2023Article
- Article
- Monitoring the Cell Cycle of Tumor Cells in Mouse Models of Human Cancer.Cold Spring Harbor perspectives in medicine · 2023Article
- Significance of RB Loss in Unlocking Phenotypic Plasticity in Advanced Cancers.Molecular cancer research : MCR · 2023Article
- Seeing is believing: the impact of RB on nuclear organization.Cell cycle (Georgetown, Tex.) · 2023Article
Corrections and comments
- Commented on by
Authors and funding
12 authors at 1 institution in 1 country.
David M Walter *Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Travis J Yates *Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Miguel Ruiz-Torres *Department of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Caroline Kim-KiselakDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
A Andrea GudielDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Charuhas DeshpandeDepartment of Pathology & Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Walter Z WangVagelos Scholars Program, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.
Michelle CicchiniDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Kate L StokesDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
John W TobiasAbramson Cancer Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA, USA.
Elizabeth BuzaDepartment of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.
David M FeldserDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. dfeldser@upenn.edu.
University of Pennsylvania · US
Funding
UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SHELLEY L BERGER · 1985 to 2026
$222.3MTranslational Research Training Program in Environmental Health SciencesT32ES019851 · NIEHS · UNIVERSITY OF PENNSYLVANIA · PI Kara A Bernstein, Trevor M Penning · 2012 to 2026
$6.0MTraining In Tumor VirologyT32CA115299 · NCI · UNIVERSITY OF PENNSYLVANIA · PI ROBERTSON, ERLE S. · 2006 to 2021
$4.7Mp53-Mediated Tumor Immune SurveillanceR01CA193602 · NCI · UNIVERSITY OF PENNSYLVANIA · PI FELDSER, DAVID · 2015 to 2019
$2.0MDeconstructing the multi-faceted roles of Rb in tumor progressionR01CA222503 · NCI · UNIVERSITY OF PENNSYLVANIA · PI FELDSER, DAVID · 2018 to 2022
$1.8MEstablishing therapeutic efficacy and uncovering mechanisms of tumor suppressionR00CA158581 · NCI · UNIVERSITY OF PENNSYLVANIA · PI FELDSER, DAVID · 2013 to 2015
$707kIdentifying Mechanisms of p53 and Rb Tumor Suppression In Small Cell Lung CancerR21CA205340 · NCI · UNIVERSITY OF PENNSYLVANIA · PI FELDSER, DAVID · 2016 to 2017
$385kEstablishing therapeutic efficacy and uncovering mechanisms of tumor suppressionK99CA158581 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI FELDSER, DAVID · 2011 to 2012
$233kNCI NIH HHS K99 CA158581NCI NIH HHS P30 CA016520NCI NIH HHS R00 CA158581NCI NIH HHS R01 CA193602NCI NIH HHS R01 CA222503NCI NIH HHS R21 CA205340NCI NIH HHS T32 CA115299NIEHS NIH HHS T32 ES019851
Abstract
Mutations in the retinoblastoma (RB) tumour suppressor pathway are a hallmark of cancer and a prevalent feature of lung adenocarcinoma
Indexed as
Cell LineageDisease ProgressionNeoplasm Metastasis3T3 CellsAdenocarcinomaAnimalsCyclin-Dependent Kinase 2Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6HEK293 CellsHumansLung NeoplasmsMaleMAP Kinase Signaling SystemMiceRetinoblastomaCDK2 protein, humanCDK4 protein, humanCDK6 protein, humanCyclin-Dependent Kinase 2Cyclin-Dependent Kinase 4Cyclin-Dependent Kinase 6
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.